MoonLake Immunotherapeutics raises $75M in equity offering of 7.1M shares at $10.50/share

MoonLake Immunotherapeutics

Offering of 7,142,857 Class A ordinary shares at $10.50 per share for gross proceeds of $75M.
Underwriting agreement with Leerink Partners LLC; expected close on November 6, 2025.
Shares offered under existing shelf registration statement on Form S-3 (File No. 333-274286).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.